Ember Therapeutics, Inc. (EMBT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ember Therapeutics, Inc. (EMBT) with AI Score 44/100 (Weak). Ember Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing regenerative medicines using bone morphogenetic protein-7 (BMP-7). Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Ember Therapeutics, Inc. (EMBT) Healthcare & Pipeline Overview
Ember Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing regenerative medicines based on bone morphogenetic protein-7 (BMP-7) technology. Their pipeline addresses osteoarthritis, chronic kidney disease, and metabolic diseases. The company holds a substantial patent portfolio related to BMP-7 and operates in the competitive biotechnology sector.
Investment Thesis
Ember Therapeutics operates in the regenerative medicine space with a focus on BMP-7 technology. Key value drivers include the advancement of their lead candidate, MT-006, through clinical trials for osteoarthritis, a large and growing market. Successful clinical trial outcomes and potential partnerships could drive significant value. The company's extensive patent portfolio provides a competitive advantage. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and the need for additional funding. With a market capitalization of $0.00B and a P/E ratio of -0.02, the company's valuation is highly dependent on the success of its clinical programs. The company's beta of -0.44 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Ember Therapeutics focuses on bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines.
- Lead product candidate MT-006 has completed Phase 2a clinical trial for osteoarthritis (OA).
- The company holds approximately 450 patents covering BMP-7 and related technologies.
- Ember Therapeutics targets diseases like chronic kidney disease (CKD), Alport's syndrome, obesity, and type 2 diabetes.
- The company's market capitalization is $0.00B, reflecting its clinical-stage status.
Competitors & Peers
Strengths
- Proprietary BMP-7 technology platform.
- Extensive patent portfolio.
- Clinical-stage product candidates.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Lack of commercialized products.
- OTC market listing.
Catalysts
- Upcoming: Publication of Phase 2a clinical trial results for MT-006 in osteoarthritis.
- Upcoming: Initiation of Phase 2b clinical trials for MT-006.
- Ongoing: Potential for strategic partnerships or collaborations with pharmaceutical companies.
- Ongoing: Advancement of MT-007 and MT-009 through preclinical development.
- Ongoing: Expansion of the BMP-7 patent portfolio.
Risks
- Potential: Clinical trial failures for MT-006 or other product candidates.
- Potential: Regulatory hurdles and delays in obtaining marketing approvals.
- Potential: Competition from other biotechnology companies developing similar therapies.
- Ongoing: Need for additional funding to support clinical development.
- Ongoing: Risks associated with operating in the OTC market.
Growth Opportunities
- Advancement of MT-006 for Osteoarthritis: Ember's lead candidate, MT-006, has completed Phase 2a clinical trials for osteoarthritis (OA). Osteoarthritis affects millions worldwide, representing a significant market opportunity. Successful completion of Phase 3 trials and subsequent regulatory approval could generate substantial revenue. The timeline for commercialization depends on clinical trial outcomes, but potential market entry could occur within the next 3-5 years.
- Development of MT-007 for Chronic Kidney Disease and Alport Syndrome: MT-007 is in preclinical development for chronic kidney disease (CKD) and Alport syndrome, both of which represent significant unmet medical needs. The market for CKD therapies is substantial and growing. Successful preclinical and clinical development of MT-007 could lead to a valuable therapeutic option. The timeline for commercialization is longer, potentially 5-7 years, due to the early stage of development.
- Expansion into Metabolic Diseases with MT-009: MT-009 is a preclinical candidate targeting metabolic diseases, including obesity and type 2 diabetes. These diseases are highly prevalent globally, creating a large market opportunity. Successful development of MT-009 could position Ember as a player in the metabolic disease space. The timeline for commercialization is estimated at 5-7 years, contingent on successful preclinical and clinical trials.
- Leveraging the BMP-7 Patent Portfolio: Ember Therapeutics holds approximately 450 patents covering BMP-7 and related technologies. This extensive patent portfolio provides a competitive advantage and potential for licensing opportunities. Strategic partnerships and out-licensing of BMP-7 technology could generate revenue and expand the company's reach. The timeline for realizing value from the patent portfolio is ongoing, with potential for near-term and long-term opportunities.
- Strategic Partnerships and Collaborations: Ember can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks. Successful partnerships could significantly enhance Ember's prospects and expedite the delivery of its therapies to patients. The timeline for securing partnerships is ongoing, with potential for near-term and long-term agreements.
Opportunities
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Out-licensing of BMP-7 technology.
- Positive clinical trial results.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Need for additional funding.
Competitive Advantages
- Extensive patent portfolio covering BMP-7 technology.
- Clinical-stage product candidates targeting unmet medical needs.
- Expertise in regenerative medicine and bone morphogenetic proteins.
- Potential for strategic partnerships to accelerate development.
About EMBT
Ember Therapeutics, Inc., founded in 2010 and headquartered in New York City, is a clinical-stage biopharmaceutical company focused on developing regenerative medicines. The company's core technology revolves around the clinical application of bone morphogenetic protein-7 (BMP-7) to address significant unmet medical needs. Ember's primary focus is the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Their lead product candidates include MT-006, which has completed a Phase 2a clinical trial for osteoarthritis; MT-007, which has completed preclinical trials for CKD and Alport syndrome; MT-008, a preclinical trial completed candidate for Alport syndrome; and MT-009, a preclinical trial completed candidate for metabolic disease. Ember Therapeutics also possesses a significant intellectual property portfolio, holding approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. The company operates in the highly competitive biotechnology industry, seeking to advance its pipeline through clinical trials and potential partnerships.
What They Do
- Develop regenerative medicines for osteoarthritis (OA).
- Develop therapies for chronic kidney disease (CKD) and Alport's syndrome.
- Research treatments for metabolic diseases like obesity and type 2 diabetes.
- Focus on the clinical application of bone morphogenetic protein-7 (BMP-7).
- Conduct preclinical and clinical trials to evaluate product candidates.
- Hold a significant patent portfolio related to BMP-7 technology.
- Seek strategic partnerships to advance development and commercialization.
Business Model
- Develop and patent regenerative medicine technologies.
- Conduct preclinical and clinical trials to validate therapies.
- Seek regulatory approval for product candidates.
- Potentially commercialize therapies directly or through partnerships.
Industry Context
Ember Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The regenerative medicine market, in particular, is experiencing increasing demand due to the aging global population and the rising prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Ember's focus on BMP-7 technology differentiates it within this competitive environment. The company's success depends on navigating regulatory hurdles and securing funding for clinical trials.
Key Customers
- Patients suffering from osteoarthritis (OA).
- Patients with chronic kidney disease (CKD) and Alport's syndrome.
- Individuals with metabolic diseases like obesity and type 2 diabetes.
- Potential pharmaceutical partners seeking to license BMP-7 technology.
Financials
Chart & Info
Ember Therapeutics, Inc. (EMBT) stock price: Price data unavailable
Latest News
No recent news available for EMBT.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EMBT.
Price Targets
Wall Street price target analysis for EMBT.
MoonshotScore
What does this score mean?
The MoonshotScore rates EMBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Joseph Hernandez
CEO
Information on Joseph Hernandez's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be required to gather information on his career history, education, previous roles, and credentials.
Track Record: Information on Joseph Hernandez's track record is not available in the provided data. Therefore, a summary of his key achievements, strategic decisions, and company milestones under his leadership cannot be provided. Further research would be required to gather this information.
EMBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ember Therapeutics may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with speculative ventures or those facing financial difficulties.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business plan and market opportunity.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Existence of a valid business plan and market opportunity.
- Experienced management team with relevant industry expertise.
- Holding of patents related to BMP-7 technology.
- Completion of Phase 2a clinical trial for MT-006.
- Focus on addressing unmet medical needs.
Common Questions About EMBT
What does Ember Therapeutics, Inc. do?
Ember Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing regenerative medicines using its proprietary bone morphogenetic protein-7 (BMP-7) technology. The company's lead product candidate, MT-006, is being developed for the treatment of osteoarthritis. Additionally, Ember is developing therapies for chronic kidney disease, Alport's syndrome, and metabolic diseases. The company aims to address significant unmet medical needs through its innovative BMP-7 platform.
What do analysts say about EMBT stock?
AI analysis is currently pending for EMBT. Given its status as an OTC-listed, clinical-stage biopharmaceutical company, analyst coverage may be limited. Key valuation metrics would likely focus on the potential market size for its target indications, the probability of success for its clinical trials, and the value of its patent portfolio. Growth considerations center on the successful advancement of its product candidates through clinical development and regulatory approval.
What are the main risks for EMBT?
Ember Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could halt the development of its product candidates. Regulatory hurdles and delays in obtaining marketing approvals could also impact the company's timeline and financial prospects. Competition from other biotechnology companies developing similar therapies poses a further challenge. Additionally, the company's reliance on external funding and its listing on the OTC market introduce financial and liquidity risks.
What are the key factors to evaluate for EMBT?
Ember Therapeutics, Inc. (EMBT) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary BMP-7 technology platform.. Primary risk to monitor: Potential: Clinical trial failures for MT-006 or other product candidates.. This is not financial advice.
How frequently does EMBT data refresh on this page?
EMBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EMBT's recent stock price performance?
Recent price movement in Ember Therapeutics, Inc. (EMBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary BMP-7 technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EMBT overvalued or undervalued right now?
Determining whether Ember Therapeutics, Inc. (EMBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EMBT?
Before investing in Ember Therapeutics, Inc. (EMBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on CEO background and track record is limited.
- Disclosure status on OTC markets is unknown.